Xzencis to support endometriosis research program

Mölnlycke, Sweden: – Pharmacovigilance and Translational Safety specialist consultancy Xzencis has committed to regular donations to a UK research program into endometriosis, a condition that significantly affects quality of life for women.

Xzencis founder and Managing Director Dr. Steffen Ernst announced that the company had committed to annual donations of almost £2000 to the PhD research program at England’s University of Derby. The program is studying the psychological factors and cognitive biases involved in the quality-of-life experiences for women living with constant endometriosis-related pain.

Incurable condition

The program is part of the Alliance for Women’s Health Research (AWHR) initiative recently launched by MediPaCe Ltd, a patient engagement company in the UK.

Endometriosis is an incurable condition in which womb lining-type tissue is transferred to other organs, causing chronic pain, infertility and depression.

The Derby University and MediPaCe team is using crowdfunding to finance a campaign that includes setting up balanced pain management programs and is now almost half way toward its target of £15,000 (€17,860), with MediPaCe and Xzencis the major donors so far.

Gender gap in patient safety

Dr. Ernst commented: “The AWHR is a new, precompetitive collaboration group that will bring together pharmaceutical and medical device companies, patient groups, and academic researchers. The aim is to improve researched and integrated healthcare options for women, and those assigned female at birth, so that they can have suitable treatment options and choices”.

“I support this important program not only as father of four daughters but also because Xzencis frequently sees drug safety issues with inadequate gender stratification, usually to the potential disadvantage of female patients,” he explained.

“I am urging all our friends and partners to join us in donating something to this very worthy and important campaign,” Steffen Ernst added.

About Xzencis AB

Xzencis provides a wide suite of expert consultancy services focused on Translational Safety Solutions: planning and executing transitions and problem solving along the entire pharmaceutical value chain from pre-clinical target to market launch and beyond.

The company’s strength is based on in-depth subject matter expertise in medicinal regulation, toxicology, clinical Patient Safety (PS) and Pharmacovigilance (PV), business administration, business development and licensing uniquely combined with hands-on business experience. These allow us to assist any life sciences company or organization with safety and regulatory issues, such as strategy development and execution, pre-clinical and clinical challenges, inbound or outbound licensing, building safety value chains, governance, Due Diligence assessments for investors and organizational design of safety departments.

Where extra personnel are required, Xzencis can call on an extensive network of senior, experienced Toxicologists, NCDS sub-discipline experts, Safety Physicians, Safety Scientists and PV Systems experts – all with tested and proven, impeccable track records.

Learn more at: www.xzencis.com

About Endometriosis

Endometriosis is a chronic condition where tissue similar to the lining of the womb grows in other places, such as the ovaries and fallopian tubes. It can affect women of all ages, including teenagers.

For many women, endometriosis has a big impact on their life and mental health with symptoms that can vary from trivial to severe, including spinal or pelvic pain, nausea, and complications in menstruation.

There is currently no cure for endometriosis, with treatment limited to addressing symptoms through painkillers, hormone medicines and contraceptives. Surgery can be used to remove patches of endometriosis tissue or affected parts of organs, typically colon, appendix, or womb (hysterectomy).

Further problems caused by endometriosis can include infertility and consequences of surgery, such as bleeding, infections, and organ damage.

About AWHR

Alliance for Women’s Health Research (AWHR) is a collaborative group uniting pharmaceutical and medical device companies, patient groups, and academic researchers to improve researched and integrated healthcare options for women.

The AWHR Initiative is the brainchild of MediPaCe, a UK-based specialist consultancy company that fosters deeper links between patient communities, pharma industry, and academia to driving strategic internal and cultural patient-centric change.

AWHR aims to harness collective voices and experiences to transform personalized healthcare options for women that integrate innovative pharmaceutical care with novel whole-person interventions to improve quality of life and outcomes.

The program seeks to shape governance and decision-making processes, co-ordinate research project and set the agenda for future collaborative work in women’s health.

The initial AWHR project focuses on those living with endometriosis-associated chronic pain and aims to provide the essential research foundation for intervention-development that integrates pharmaceutical approaches with whole-person therapies to balanced pain management options to maximize patient outcomes and quality of life.

Learn more at: https://medipace.com/about-us/

Resources

Click on MediPaCe launches Alliance for Women’s Health Research (AWHR) Initiative to learn more.
Click on Join Us in Driving Personalized Care in Endometriosis to make a donation via GoFundMe.